

Cat. No. MHC-HM456TP

Description

Source Recombinant PE-Labeled Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-Labeled Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer is assembled by biotinylated monomer and PE-Labeled streptavidin

It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVGAVGVGK peptide.

Accession

NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVGAVGVGK

Wavelength

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

Endotoxin

Less than 1 EU per µg by the LAL method.

Formulation and Storage**Formulation**

Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage

-20 to -80°C for 12 months as supplied from date of receipt -80°C for 3 months after reconstitution Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.